[Federal Register Volume 85, Number 44 (Thursday, March 5, 2020)] [Notices] [Page 12935] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2020-04534] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Jeffrey Thruston at 301-594-5179 or [email protected]. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. SUPPLEMENTARY INFORMATION: Technology description follows: Alpha-Synuclein RT-QuIC: An Ultrasensitive Assay for the Detection of Alpha-Synuclein Seeding Activity Associated With Synucleinopathies Description of Technology: Synucleinopathies are a category of neurodegenerative diseases defined by the abnormal aggregation and accumulation of misfolded alpha-synuclein protein molecules within the brain. These aggregates are of particular concern to humans as they are a primary cause of Parkinson's disease, dementia with Lewy bodies, and other neurological disorders. This technology enables rapid, economical and ultrasensitive detection of disease-associated forms of alpha- synuclein as biomarkers or indicators of synucleinopathy in a biological sample. Specifically, alpha-synuclein aggregates (contained in a biological sample) seed the polymerization of vast stoichiometric excesses of recombinant, normally folded alpha-synuclein into amyloid fibrils that are then detectable by an amyloid-sensitive fluorescent dye. This reaction can thereby amplify the seeds in a biospecimen by many orders of magnitude. For example, in its current embodiment, this assay has been used to detect alpha-synuclein seeds in cerebral spinal fluid from living patients with Parkinson's disease and Lewy-body dementia, giving high diagnostic sensitivity and specificity with unprecedented speed. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. Potential Commercial Applications:Pre-mortem diagnosis of synucleinopathies, including Parkinson's disease and Lewy-body dementia A monitor of the disease progression of dementia and synucleinopathies Clinical trial/drug development companion diagnostic Competitive Advantages: Uses a consistent, concentrated source of truncated alpha- synuclein protein substrate Capable of disease detection prior to onset of symptoms Rapid and economical Development Stage: Research Use Inventors: Byron Caughey (NIAID), Bradley Groveman (NIAID), Christina Orru (NIAID), Lynne Raymond (NIAID) Publications: Groveman, Bradley R et al. ``Rapid and ultra- sensitive quantitation of disease-associated [alpha]-synuclein seeds in brain and cerebrospinal fluid by [alpha]Syn RT-QuIC.'' Acta Neuropathologica Communications vol. 6(1):7, 9 Feb. 2018. Licensing Contact: To license this technology, please contact Jeffrey Thruston at 301-594-5179 or [email protected], and reference E-233-2017-0. Dated: February 25, 2020. Wade W. Green, Acting Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2020-04534 Filed 3-4-20; 8:45 am] BILLING CODE 4140-01-P